StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Stock analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Wednesday. The firm set a “sell” rating on the stock.

A number of other research firms have also recently commented on VNRX. Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Tuesday, March 4th.

VolitionRx Stock Up 1.6 %

NYSE:VNRX opened at $0.59 on Wednesday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.09. The stock has a market capitalization of $54.58 million, a PE ratio of -1.64 and a beta of 1.09. The stock’s 50-day moving average price is $0.61 and its 200-day moving average price is $0.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new position in VolitionRx in the 4th quarter valued at about $29,000. Millennium Management LLC purchased a new position in VolitionRx in the 4th quarter worth approximately $36,000. Northern Trust Corp lifted its stake in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Geode Capital Management LLC lifted its stake in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.